Key Points
- Christopher Heery sold 7,437 shares of Arcellx on Jan. 13 at an average price of $65.51 for a total of $487,197.87, reducing his ownership by 20.06% to 29,631 shares (worth about $1.94M).
- Heery also executed recent sales of 6,131 shares on Jan. 12 at $64.15 and 340 shares on Nov. 17 at $90, showing multiple insider dispositions in a short period.
- Arcellx (ACLX) trades around $66.75 with a one‑year range of $47.86–$94.07, remains loss‑making (negative EPS and margins), yet carries a consensus analyst view of "Moderate Buy" with a $112.22 price target.
Arcellx, Inc. (NASDAQ:ACLX - Get Free Report) insider Christopher Heery sold 7,437 shares of the firm's stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $65.51, for a total transaction of $487,197.87. Following the completion of the sale, the insider owned 29,631 shares of the company's stock, valued at $1,941,126.81. The trade was a 20.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Christopher Heery also recently made the following trade(s):
- On Monday, January 12th, Christopher Heery sold 6,131 shares of Arcellx stock. The shares were sold at an average price of $64.15, for a total transaction of $393,303.65.
- On Monday, November 17th, Christopher Heery sold 340 shares of Arcellx stock. The stock was sold at an average price of $90.00, for a total transaction of $30,600.00.
Arcellx Price Performance
Shares of ACLX opened at $66.75 on Wednesday. Arcellx, Inc. has a one year low of $47.86 and a one year high of $94.07. The company has a market cap of $3.86 billion, a PE ratio of -16.98 and a beta of 0.36. The stock has a 50-day moving average of $73.26 and a 200-day moving average of $74.89.
Arcellx (NASDAQ:ACLX - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by ($0.03). Arcellx had a negative return on equity of 51.13% and a negative net margin of 607.01%.The firm had revenue of $4.95 million during the quarter, compared to the consensus estimate of $11.24 million. Analysts expect that Arcellx, Inc. will post -1.58 EPS for the current fiscal year.
Institutional Investors Weigh In On Arcellx
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Avanza Fonder AB lifted its holdings in Arcellx by 64.3% during the fourth quarter. Avanza Fonder AB now owns 2,003 shares of the company's stock worth $131,000 after acquiring an additional 784 shares during the period. Congress Asset Management Co. increased its stake in shares of Arcellx by 2.8% during the 4th quarter. Congress Asset Management Co. now owns 25,999 shares of the company's stock worth $1,695,000 after purchasing an additional 697 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Arcellx by 48.4% in the 4th quarter. SG Americas Securities LLC now owns 12,041 shares of the company's stock worth $785,000 after purchasing an additional 3,926 shares during the period. Harbour Capital Advisors LLC purchased a new position in Arcellx in the fourth quarter valued at approximately $242,000. Finally, CIBC Bancorp USA Inc. bought a new position in Arcellx during the third quarter valued at $300,000. Hedge funds and other institutional investors own 96.03% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts have commented on ACLX shares. Canaccord Genuity Group restated a "buy" rating and set a $130.00 price target on shares of Arcellx in a research note on Monday, December 8th. Wolfe Research initiated coverage on shares of Arcellx in a report on Tuesday, November 18th. They set a "peer perform" rating for the company. Citigroup restated a "buy" rating on shares of Arcellx in a report on Monday, November 24th. Needham & Company LLC reaffirmed a "buy" rating and issued a $105.00 price target on shares of Arcellx in a research report on Monday, December 8th. Finally, Wells Fargo & Company began coverage on Arcellx in a report on Monday, December 22nd. They set an "overweight" rating and a $100.00 price objective for the company. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $112.22.
View Our Latest Stock Report on Arcellx
About Arcellx
(
Get Free Report)
Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company's proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.
The company's pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
